Domain Therapeutics promotes Stephan Schann as Chief Scientific Officer (CSO)

Domain Therapeutics promotes Stephan Schann as Chief Scientific Officer (CSO)

Strasbourg, France – Montreal, Canada – Boston, United States, February 27, 2024 – Domain Therapeutics (“Domain” or “the Company”), a clinical-stage global biopharmaceutical company developing innovative drug candidates in immuno-oncology targeting G Protein-Coupled Receptors (GPCRs), today announces the expansion of the Company’s executive management team with the appointment of Stephan Schann asChief Scientific Officer (CSO). Stephan will oversee the development of Domain’s proprietary pipeline and its highly innovative R&D center based in Strasbourg, France.

Stephan has been with Domain since its inception in 2008 and has been promoted from his previous role as Vice President of Research. He has been instrumental in leading and executing Domain’s research initiatives, raising funds, building its intellectual property portfolio, and advancing its proprietary R&D programs and collaborations with pharma partners. Stephan has also contributed significantly to the Company’s scientific achievements and strategic direction. With over two decades of leadership experience in the biopharmaceutical industry, Stephan has extensive expertise in biomedical research. He has successfully managed several programs from idea through to early development.

In his new role, Stephan will lead Domain’s scientific strategy, coordinating with the CEO and executive management team to drive the Company’s pipeline of GPCR targeted cancer immunotherapies towards the next R&D milestones. This includes the continued development of novel drug candidates DT-7012, a best-in-class Treg-depleting anti-CCR8 monoclonal antibody and DT-9045, a first-in-class PAR2 antagonist, while advancing the EP4R program’s DT-9081, currently in its Phase I ascending dose study.

Prior to his time with Domain, Stephan held several prominent roles including Head of Medicinal Chemistry at Faust Pharmaceuticals and Senior Scientist at Evotec. Stephan holds two Master’s Degrees in Organic and Medicinal Chemistry as well as a Ph.D. in Medicinal Chemistry from the University of Strasbourg, France.

Dr. Tony Johnson, President and Chief Executive Officer of Domain Therapeutics, said: “We are thrilled to have Stephan be promoted into the role of Chief Scientific Officer. It has been a privilege for our teams to work with Stephan to bring our GPCR targeted immunotherapies to the clinic, backed by robust pre-clinical evidence built under his expert guidance. His visionary leadership, scientific acumen, knowledge of Domain and unwavering dedication to our shared mission make him ideal to lead our remarkable research team as we strive to progress our pipeline of first-in-class and best-in-class GPCR targeted cancer immunotherapies to deliver effective treatments to patients. Stephan’s appointment reinforces our commitment to growth, solidifying our position as the leading GPCR immuno-oncology company, now expanding our reach into the US markets.”

Stephan Schann, newly appointed Chief Scientific Officer of Domain Therapeutics, commented: “I have always been deeply impressed by the commitment of Domain’s staff, scientists, management and Board of Directors to advancing its science. It is a true honor to be working with such a dynamic and driven leadership team. I look forward to continuing to support the Company and to further developing Domain’s unique precision research approach, translating our groundbreaking science into meaningful, differentiated and life-saving treatments for cancer patients. Domain is a highly innovative company built on a foundation of leading scientific expertise in pioneering GPCR in immuno-oncology that has the potential to be a game-changer in the coming years.”




For more information, please contact:

ICR Consilium
Amber Fennell, Namrata Taak, Andrew Stern
Tel: +44 (0)20 3709 5813

Yucatan (for French media)
Annie-Florence Loyer
Tel: +33 (0)


About Domain Therapeutics

Domain Therapeutics, a clinical-stage biopharmaceutical company operating in France and Canada, focuses on developing innovative immunotherapies targeting G Protein-Coupled Receptors (GPCRs), one of the most important drug target classes, to unlock new possibilities in cancer. As a leader in GPCRs in immuno-oncology, Domain sees cancer differently, using a precise biomarker strategy to address the specific needs of patients based on unique signatures of individual cancers. Two decades of solid expertise in GPCR, validated by multiple pharma partnerships, associated to target identification and drug discovery platform enables the Company to enhance the understanding of cancer and deliver innovative immunotherapies to patients.

Domain’s proprietary programs include DT-7012, its Treg-depleting CCR8 antibody, DT-9045, its PAR2 NAM antagonist, DT-9081, its EP4 receptor antagonist and M1069, an A2aR/A2b receptor antagonist identified in partnership with Merck KGaA, and alongside a rich, optimized pipeline of first-in-class GPCR targets selected through Domain’s proprietary cross-validation drug discovery and development platform.

The Company raised €39m ($42m) in early 2022 to progress preclinical and clinical development of its high-value drug candidates to address GPCR-mediated immunosuppression in immuno-oncology. Domain is backed by a syndicate of leading international venture capital funds from Europe, Asia and North America.